B&B Pharmacy Recalls PAPA/PHENTO Injection Due to Sterility Concerns
Pacific Healthcare, Inc dba B&B Pharmacy is recalling PAPA/PHENTO Injection vials because an FDA inspection found GMP violations that may affect sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or infection.
Plain-English summary
Pacific Healthcare, Inc dba B&B Pharmacy is recalling PAPA/PHENTO (15mg/0.8333mg/ml) Injection, 5 mL vials. The recall was initiated because an FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility.
The affected product is a prescription injection distributed in California and New Jersey. The specific lot code is 07082015@4, with an expiration date of 1/5/2016.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or the recalling firm for instructions on return or replacement.
The recalled product
- Product
- PAPA/PHENTO (15mg/0.8333mg/ml) Injection, 5 mL vial, Rx, B & B Health Mart Pharmacy, Bellflower, CA
- Manufacturer
- Pacific Healthcare, Inc dba B&B Pharmacy
- Category
- Drug — Injection
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 07082015@4
- exp 1/5/2016
Distribution
Part of a larger recall action
This product is one of 16 recalled by Pacific Healthcare, Inc dba B&B Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 16 products in this recall →Related recalls
Same manufacturer · Pacific Healthcare, Inc dba B&B Pharmacy
See all →- SevereNandrolone Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SevereB&B Pharmacy Recalls PAPA/PHENTO Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-18
- SevereTestosterone Cypionate Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SevereStanozolol Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SeverePGE 25mcg/ml Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFallon Wellness Pharmacy Recalls PAPA/PHEN/PROST Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereFallon Wellness Pharmacy Recalls Papaverine Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereB-Complex Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereB-Complex Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereLipotropic B-12 Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereFDA Recalls Bevacizumab Intravitreal Injection Due to Sterility Concerns
FDA (Drugs) · 2019-09-18